CA2936550C - Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators - Google Patents

Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators Download PDF

Info

Publication number
CA2936550C
CA2936550C CA2936550A CA2936550A CA2936550C CA 2936550 C CA2936550 C CA 2936550C CA 2936550 A CA2936550 A CA 2936550A CA 2936550 A CA2936550 A CA 2936550A CA 2936550 C CA2936550 C CA 2936550C
Authority
CA
Canada
Prior art keywords
oxo
alkyl
carbonitrile
pheny1
hexahydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2936550A
Other languages
English (en)
French (fr)
Other versions
CA2936550A1 (en
Inventor
Eric Anderson
Xin Jiang
Christopher Bender
Gary Bolton
Bradley William Caprathe
Chitase Lee
William ROARK
Pamela Donner
Rolf Wagner
Jason Shanley
Howard Heyman
Allan Krueger
Hui-Ju Chen
Michael ROZEMA
David Grampovnik
Melean Visnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CA2936550A1 publication Critical patent/CA2936550A1/en
Application granted granted Critical
Publication of CA2936550C publication Critical patent/CA2936550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2936550A 2014-01-24 2015-01-23 Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators Active CA2936550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931291P 2014-01-24 2014-01-24
US61/931,291 2014-01-24
PCT/US2015/012579 WO2015112792A1 (en) 2014-01-24 2015-01-23 Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Publications (2)

Publication Number Publication Date
CA2936550A1 CA2936550A1 (en) 2015-07-30
CA2936550C true CA2936550C (en) 2022-07-26

Family

ID=52484552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936550A Active CA2936550C (en) 2014-01-24 2015-01-23 Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Country Status (8)

Country Link
US (1) US9464082B2 (OSRAM)
EP (1) EP3097089B1 (OSRAM)
JP (1) JP6530758B2 (OSRAM)
CN (1) CN107074801B (OSRAM)
CA (1) CA2936550C (OSRAM)
MX (1) MX372772B (OSRAM)
TW (1) TWI670263B (OSRAM)
WO (1) WO2015112792A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
US11059792B2 (en) * 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
WO2018095953A1 (de) 2016-11-23 2018-05-31 Bayer Cropscience Aktiengesellschaft 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
BR112020025605A2 (pt) * 2018-06-15 2021-03-23 Reata Pharmaceuticals, Inc. compostos de pirazol e imidazol para inibição de il-17 e rorgama
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20250025465A1 (en) * 2021-11-17 2025-01-23 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142889A1 (en) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents
EP1438293A2 (en) * 2001-09-19 2004-07-21 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
HUE038046T2 (hu) * 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok

Also Published As

Publication number Publication date
JP2017503840A (ja) 2017-02-02
MX2016009589A (es) 2016-10-28
MX372772B (es) 2020-06-29
WO2015112792A1 (en) 2015-07-30
JP6530758B2 (ja) 2019-06-12
US9464082B2 (en) 2016-10-11
TWI670263B (zh) 2019-09-01
CN107074801A (zh) 2017-08-18
EP3097089A1 (en) 2016-11-30
CN107074801B (zh) 2021-11-05
TW201605808A (zh) 2016-02-16
US20150225397A1 (en) 2015-08-13
EP3097089B1 (en) 2021-02-24
CA2936550A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CA2936550C (en) Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP2892910B1 (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity
CA3210224A1 (en) Cdk inhibitors and methods of use thereof
CA2822071C (en) Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CA2981404C (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
CA2956465A1 (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
WO2021150806A1 (en) Heterocyclic compounds as anti-viral agents
MX2014014658A (es) Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos.
JP2016533372A (ja) 縮合複素環化合物、その調製方法、医薬組成物及びその使用
WO2017156179A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
JP2012529525A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
CA3174982A1 (en) Rsv inhibiting 3-substituted quinoline and cinnoline derivatives
JP2021534250A (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト
AU2010216219A1 (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
KR20240121746A (ko) 테트라하이드로피리다진, 이를 포함하는 조성물, 및 이의 용도
JP7182548B2 (ja) アザインデノイソキノリン化合物およびその使用
EP2488511A1 (en) Pyrazole inhibitors of phosphatidylinositol 3-kinase
EP4423067A1 (en) Sarm1 modulators, preparations, and uses thereof
CA3240538A1 (en) Oxer1 antagonists and uses thereof
WO2022010882A1 (en) Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2020210246A1 (en) Heterocyclic compounds as rsv inhibitors
HK1196355A (en) Compounds useful as inhibitors of choline kinase
HK1146057A (en) N-heterocyclic compounds useful as inhibitors of janus kinases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200122

EEER Examination request

Effective date: 20200122

EEER Examination request

Effective date: 20200122